Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414373 | 0.91 | HDAC1 (0.52) | CA12CA1CA2CA9HDAC1 | |
| SCHEMBL9269708 | 0.84 | HDAC1 (0.51) | CA12CA1CA2CA9HDAC1 | |
| SCHEMBL28853829 | 0.84 | PTGS2 (0.53) | CA12CA1CA2CA9HDAC1 | |
| SCHEMBL1650589 | 0.83 | CA1 (0.51) | CA12CA1CA2CA9HDAC1 | |
| SCHEMBL30155019 | 0.83 | CA1 (0.51) | CA12CA1CA2CA9HDAC1 | |
| SCHEMBL8666600 | 0.80 | HDAC1 (0.55) | CA1CA2HDAC1HDAC8CYP19A1 | |
| SCHEMBL1275476 | 0.80 | HDAC1 (0.48) | CA12CA1CA2CA9HDAC1 | |
| SCHEMBL9800386 | 0.80 | HDAC1 (0.45) | CA12CA1CA2CA9HDAC1 | |
| Sulfuric Acid SCHEMBL1491064 | 0.79 | CA1 (0.48) | CA12CA1CA2CA9HDAC1 | |
| SCHEMBL1457933 | 0.79 | CYP19A1 (0.48) | CA12CA1CA2CA9HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0655912-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ELEVATED INTRAOCULAR PRESSURE | GLAXO GROUP LIMITED (GB) | 1995-06-07 | — | — | EP | claimed |
| WO-1994003162-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ELEVATED INTRAOCULAR PRESSURE | GLAXO GROUP LIMITED (GB) | 1994-02-17 | — | — | WO | claimed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7862807-B2 | Dendrimers as molecular translocators | UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2011-01-04 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010004580-A2 | PROCESS FOR PREPARING INDOLE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-01-14 | — | — | WO | disclosed |
| US-20090311249-A1 | Capecitabine Combination Therapy | ARIAD PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| WO-2009118753-A2 | PROCESS FOR PREPARATION OF NARATRIPTAN HYDROCHLORIDE | USV LIMITED (IN) | 2009-10-01 | — | — | WO | disclosed |
| EP-1545462-A4 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | UNIV CALIFORNIA (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1744784-A2 | FORMULATIONS OF ANTI-PAIN AGENTS AND METHODS OF USING THE SAME | Becton, Dickinson and Company (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060216265-A1 | Dendrimers as molecular translocators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-09-28 | — | — | US | disclosed |
| EP-0927159-A1 | POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | Medinox, Inc. (US) | 1999-07-07 | — | — | EP | disclosed |
| US-5916910-A | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore | MEDINOX, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1998055453-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0866695-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | Medinox, Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1998011066-A1 | POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | MEDINOX, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998009626-A1 | METHODS FOR IN VIVO REDUCTION OF IRON LEVELS AND COMPOSITIONS USEFUL THEREFOR | MEDINOX, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1997018805-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | MEDINOX, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| EP-0655912-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ELEVATED INTRAOCULAR PRESSURE | GLAXO GROUP LIMITED (GB) | 1995-06-07 | — | — | EP | disclosed |
| WO-1994003162-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ELEVATED INTRAOCULAR PRESSURE | GLAXO GROUP LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311249-A1 | Capecitabine Combination Therapy | RICTOR, MTOR, EIF4E | CA12 2592/4885CA1 4199/4885CA2 3100/4885 |
| US-20060216265-A1 | Dendrimers as molecular translocators | SLC29A1, SLC29A2, TSPO | CA12 4480/4885CA1 4290/4885CA2 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.